Navigation Links
The Board of Directors of Kinex Pharmaceuticals Appoints Dr. David Hangauer as Chief Scientific Officer
Date:5/17/2011

BUFFALO, N.Y., May 17, 2011 /PRNewswire/ -- Kinex Pharmaceuticals, LLC announced today that Dr. David Hangauer, who served as the Founding Senior Vice President of Research, will be appointed as Chief Scientific Officer of the Company.  

Dr. Johnson Lau, Chairman and Chief Executive Officer, stated, "David discovered and designed both of our lead compounds, KX01 and KX02. He is the soul of our scientific discovery programs. I have worked together with him for the last 7 years and he is always at his best, both scientifically and from his managing of the scientific team. I am honored that he has accepted the Chief Scientific Officer position and I look forward to working with him to grow Kinex Pharmaceuticals from a scientific perspective."

Dr. Hangauer is a leader in the field of medicinal chemistry.  Following doctoral studies in chemistry at The University at Buffalo, he spent nine years at Merck Sharp and Dohme Research Laboratories where he directed a variety of drug discovery projects and, in addition, was an early pioneer in the area of structure-based drug design.  In 1989, he returned to academia and joined the chemistry faculty at The University at Buffalo where he has had a productive research career that focused initially on developing a new approach to the design of protein kinase inhibitors which led to Mimetica™, the patented technology Kinex Pharmaceuticals licensed from The University at Buffalo and upon which the company was originally based.

Dr. Hangauer's academic research is focused on the energetics of drugs binding to their receptors and has published extensively in this area. He has taught a range of courses to graduate and undergraduate students in medicinal and organic chemistry.  

Dr. Hangauer's expertise has been sought by pharmaceutical and biotechnology companies worldwide, including Lederle /Wyeth-Ayerst Research Laboratories, New Medical Technologies, Sphinx/Eli Lilly Pharmaceuticals Inc., Yuhan Corporation, Periodontix, Inc., ICAgen, Inc., ARPIDA, Scientific Advisory Board & Founding Scientist, Suntory Pharmaceuticals Research Laboratories and Signal Pharmaceuticals, Inc. Most notably he led the chemistry effort at Hypnion, Inc., that resulted in the discovery and development of an insomnia drug.  The Company was sold to Eli Lilly in 2009 for more than $300 million and its major asset was the insomnia drug that was designed and discovered under the leadership of Dr. Hangauer.

Dr. Allen Barnett, President Emeritus, states, "David well deserves this recognition. He is indeed the soul of Kinex Pharmaceuticals' discovery programs. I am delighted to have the opportunity to continue supporting David and his scientific programs and I am confident that he is going to make many more major discoveries in the years to come."

Dr. Rudolf Kwan, Chief Medical Officer, states, "David is a great scientist to work with. He can translate complex scientific questions into simple solutions. He also understands the clinical needs and is helping the clinical team to shape the development programs."

Dr. David Hangauer states, "Kinex Pharmaceuticals has evolved nicely, thanks to all of the members of the management team. I am proud to be part of this innovative team and will continue my efforts to assist the Company in discovering more novel therapies for important unmet medical needs.  Kinex will prosper as a business by focusing our efforts on the discovery and development of novel drugs that provide major benefits to patients, and it is this contribution to humanity that provides the most satisfaction for scientists such as me."

About Kinex Pharmaceuticals, LLC

Kinex Pharmaceuticals, headquartered in Buffalo, New York, USA, is using its proprietary technologies Mimetica™ and Opal™ to discover and develop novel drugs for oncology and immune-modulatory diseases.  More information of Kinex Pharmaceuticals can be found at  www.kinexpharma.com

Kinex Pharmaceuticals, LLC – Caution Regarding Forward-looking Information

Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, Kinex Pharmaceuticals cautions investors that any forward-looking statements or projections made by Kinex Pharmaceuticals, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected.

Kinex Inquiries:

Lyn M. Dyster, Ph.D.
VP, Operations
Kinex Pharmaceuticals
New York Center of Excellence
701 Ellicott Street
Buffalo, NY 14203
USA
Tel: 716.898.8626
E-mail: ldyster@kinexpharma.com


'/>"/>
SOURCE Kinex Pharmaceuticals, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Inhibikase Therapeutics Elects Steven C. Gilman, Ph.D., to Board of Directors
2. HYCOR Expands Board of Directors to Support Growth in Key Areas
3. Instacare Corp. Board of Directors Considers Recent Merger Proposal Inadequate
4. The Board of Directors of Kinex Pharmaceuticals Appoints Dr. Allen Barnett as President Emeritus and Dr. Johnson Lau as Chief Executive Officer
5. TriReme Medical Lines Up Asian Strategy With Key Appointment of New Board Members
6. Qforma Appoints New Member to Board of Directors
7. Abaxis Appoints Vernon Altman to Board of Directors
8. TeleTrackings Patient Flow Dashboard XT™ Stops Operational Problems Before They Start
9. Hospira Board Authorizes $1 Billion Share Repurchase Program
10. Thomas Mac Mahon Joins SynapDx Corporations Board of Directors
11. Valeant Pharmaceuticals Responds to Cephalon Boards Letter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... Calif. , Feb. 9, 2016 /PRNewswire/ - Nevro ... company that is providing innovative evidence-based solutions for the ... release financial results for the fourth quarter and full ... 29, 2016. Company management will host a conference call ... Time) on Monday, February 29, 2016. www.nevro.com ...
(Date:2/9/2016)... ("Unilife" or "Company") (NASDAQ: UNIS ; ASX: UNS), a ... financial results for the second quarter of fiscal 2016 (three months ... Financial Results for the Second Quarter of Fiscal ... Revenue for the second quarter of fiscal 2016 was $4.5 million, ... receipts from customers for the second quarter of fiscal 2016 were ...
(Date:2/9/2016)... February 9, 2016 QGEN ... collaboration with 10x Genomics to develop and promote ... and bioinformatics. --> QGEN ; Frankfurt ... 10x Genomics to develop and promote comprehensive solutions ... --> QIAGEN N.V. (NASDAQ: QGEN ...
Breaking Medicine Technology:
(Date:2/9/2016)... Milwaukee, WI (PRWEB) , ... February 09, 2016 ... ... Bon-Ton, Bergner’s, Boston Store, Carson’s, Elder-Beerman, Herberger’s and Younkers department stores, announced it ... Medical College of Wisconsin Cancer Center, Holden Comprehensive Cancer Center at the University ...
(Date:2/9/2016)... ... 09, 2016 , ... IsoComforter, Inc., one of the Nation’s ... designed, innovative shoulder wrap. The newly designed shoulder wrap has been specifically ... and shoulder to promote faster healing. It is highly recommended for arm or ...
(Date:2/9/2016)... ... February 09, 2016 , ... i2i Systems, an early innovator ... preliminary data vendors in the latest KLAS report, Population Health Management 2015: How Far ... developing market for population health management (PHM). The latest KLAS Report, leveraging over ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... newly redesigned website, federallabs.org . The site houses a wealth of federal ... federal technologies through the process called technology transfer (T2). As a network of ...
(Date:2/8/2016)... ... ... The Valentine’s Season is famous for gift giving with flowers, chocolates and other tokens of ... This year, for more than 5.6 million Americans suffering with Alzheimer’s, those store bought gifts ... them of the lives they’ve led and the people they’ve touched. , That’s ...
Breaking Medicine News(10 mins):